The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
Clinical analysis of 0.5 % loteprednol etabonate ophthalmic suspension after laser epithelial keratomileusis
Author(s): 
Pages: 2519-2521
Year: Issue:  15
Journal: The Journal of Practical Medicine

Keyword:  角膜磨镶术激光原位氯替泼诺上皮下角膜混浊眼压;
Abstract: 目的:观察准分子激光上皮下角膜磨镶术(laser epithelial keratomileusis,LASEK)术后应用0.5%氯替泼诺混悬滴眼液的临床效果,包括角膜上皮下雾状混浊(Haze)、眼压增高发生情况.方法:总计接受LASEK患者176例345眼,分为试验组84例165眼,术后应用0.5%氯替泼诺混悬滴眼液患者,对照组92例180眼,术后应用0.1%氟米龙滴眼液患者,观察术后6个月时Haze发生率、6个月内眼压增高的发生率,采用x2检验进行统计学分析.结果:试验组与对照组6个月时术后Haze发生率分别为9.70%(16眼)和17.22%(31眼),两者差异有统计学意义(P<0.05);术后6个月内眼压增高发生率分别为3.64%(6眼)和10.00%(18眼),两者差异有统计学意义(P<0.05).结论:与0.1%氟米龙滴眼液相比,LASEK术后应用0.5%氯替泼诺混悬滴眼液引起眼压增高的发生率明显降低,可有效预防Haze发生,临床效果安全有效.
Related Articles
No related articles found